Patti Duprey
Family · Kennebunk, MENPI 1881672988
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $25,833 of the $34,637 with a category attached, or 74.6%. Novo Nordisk accounts for 82.7% of it on its own, with 10 other manufacturers making up the rest. Reporting peaked in 2022 at $17,919 and has fallen 89.6% since, to $1,859 in 2025. Among family clinicians in ME with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 84 payments — averaging $412.34 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$29K
- Cequr Corporation$3K
- Medtronic$1K
- Boehringer Ingelheim$427
- Dexcom, Inc.$288
- AstraZeneca$221
- plus $459 from 5 others
What the payments were for
- Speaking & faculty fees$25,83375%
- Travel & lodging$5,25315%
- Food & beverage$3,31810%
- Education$2131%
- Other$200%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novo Nordisk | 45 | $28,650 |
| Cequr Corporation | 4 | $3,110 |
| Medtronic | 14 | $1,480 |
| Boehringer Ingelheim | 9 | $427 |
| Dexcom, Inc. | 3 | $288 |
| AstraZeneca | 2 | $221 |
| Bayer | 2 | $145 |
| Abbott | 2 | $132 |
| Sanofi-aventis U.S. LLC | 1 | $104 |
| Tandem Diabetes Care, Inc. | 1 | $63 |
| Lilly USA, LLC | 1 | $15 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- RYBELSUS$17,278
- Ozempic$8,763
- CeQur Simplicity$3,110
- INPEN SMART INSULIN DELIVERY SYSTEM$597
- InPen$408
- JARDIANCE$250
- DEXCOM G7 GSS (161)$158
- DEXCOM STELO GLUCOSE BIOSENSOR$158
- Kerendia$125
- FARXIGA$124
- FreeStyle Libre$112
- TZIELD$104
How this compares
$34,637 in reported general payments places this provider in the 95th percentile of 545 family providers in Maine.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 160 | $252,433 |
| Tresiba Flextouch U-200Insulin Degludec | 90 | $106,039 |
| JardianceEmpagliflozin | 76 | $95,874 |
| Omnipod 5 Dexg7g6 Pods (Gen 5)Insulin Pump Cart,auto,bt,g6/7 | 41 | $63,714 |
| MounjaroTirzepatide | 19 | $19,922 |
| Fiasp FlextouchInsulin Aspart (Niacinamide) | 29 | $18,898 |
| FiaspInsulin Aspart (Niacinamide) | 13 | $18,075 |
| Tresiba Flextouch U-100Insulin Degludec | 27 | $14,999 |
| Novolog FlexpenInsulin Aspart | 31 | $7,032 |
| NovologInsulin Aspart | 11 | $5,506 |
| Nano 2nd Gen Pen NeedlePen Needle, Diabetic | 30 | $4,400 |
| HumalogInsulin Lispro | 13 | $4,064 |
| Metformin Hcl ErMetformin Hcl | 53 | $431 |
| Rosuvastatin Calcium | 31 | $411 |
| Duloxetine Hcl | 14 | $267 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic, Fiasp, Novolog | $28,650 | $276,013184 claims |
| Boehringer IngelheimJardiance | $427 | $95,87476 claims |
| Lilly USA, LLCMounjaro, Humalog | $15 | $23,98632 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 545 family providers in Maine.
Other family in Kennebunk
- Julie HazeltonKennebunk$2K
- Mia RapollaFalmouth$193K
- Amanda WilliamsPortland$8K
- Jamie PiacentiniScarborough$6K
- Rosemary PainePortland$6K
- Brea SwihartAugusta$5K
- Kristen Schroeder-CyrBrunswick$5K
- Liana KellyBrunswick$5K
- Natalie BubierLewiston$5K
- Holly JamesYork$4K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.